Core Viewpoint - Ericsson's stock has shown strong performance, with a 7.8% increase over the past month and reaching a new 52-week high of $10.53, although its year-to-date gain of 8.1% lags behind the broader sector and industry performance [1]. Financial Performance - Ericsson has consistently exceeded earnings expectations, reporting an EPS of $0.27 against a consensus estimate of $0.23 in its last earnings report [2]. - For the current fiscal year, Ericsson is projected to earn $0.63 per share on revenues of $24.6 billion, reflecting a -7.35% change in EPS and a 1.84% change in revenues [3]. - The next fiscal year forecasts an EPS of $0.71 on revenues of $25.32 billion, indicating a year-over-year growth of 14.02% in EPS and 2.94% in revenues [3]. Valuation Metrics - Ericsson's stock trades at 16.6 times the current fiscal year EPS estimates, below the peer industry average of 24.8 times [7]. - On a trailing cash flow basis, the stock trades at 16.2 times compared to the peer group's average of 18.7 times, with a PEG ratio of 1.97 [7]. Zacks Rank and Style Scores - Ericsson holds a Zacks Rank of 2 (Buy) due to rising earnings estimates, making it a suitable choice for investors looking for stocks with strong potential [8]. - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of B, resulting in a combined VGM Score of A [6]. Industry Context - The Wireless Equipment industry is performing well, ranking in the top 25% of all industries, providing favorable conditions for both Ericsson and its peers [11]. - Clearfield, Inc. is highlighted as a strong competitor with a Zacks Rank of 1 (Strong Buy) and impressive earnings performance, indicating a competitive landscape [9][10].

Core Viewpoint - Pathward Financial (CASH) has shown strong stock performance, with a 16.7% increase over the past month and a 20.7% rise since the beginning of the year, outperforming both the Zacks Finance sector and the Zacks Banks - Northeast industry [1] Performance Metrics - The stock reached a new 52-week high of $86.92 recently [1] - Pathward has consistently exceeded earnings expectations, reporting an EPS of $1.57 against a consensus estimate of $1.38 in its last earnings report [2] - For the current fiscal year, Pathward is projected to achieve earnings of $8.45 per share on revenues of $825.7 million, reflecting a 7.37% increase in EPS and a 0.84% increase in revenues [3] Valuation Metrics - Pathward's stock trades at 10.1 times the current fiscal year EPS estimates, which is above the peer industry average of 9.4 times [7] - On a trailing cash flow basis, the stock trades at 7.9 times compared to the peer group's average of 11.8 times, positioning Pathward favorably for value investors [7] Style Scores - Pathward has a Value Score of A, with Growth and Momentum Scores of B, resulting in a combined VGM Score of A [6] Zacks Rank - The stock holds a Zacks Rank of 2 (Buy), supported by positive earnings estimate revisions from analysts, indicating potential for further gains [8]

Core Viewpoint - Annaly Capital Management Inc. (NLY) is set to report its fourth-quarter 2025 results on January 28, with expectations of a significant year-over-year increase in net interest income (NII) while earnings are projected to remain unchanged [1][8]. Financial Performance - The consensus estimate for fourth-quarter NII is $469 million, indicating a rise from the previous year's NII of $187.3 million [3]. - Earnings per share (EPS) estimates have remained unchanged at 72 cents, reflecting no change from the year-ago quarter [3]. Market Conditions - The Federal Reserve's two interest rate cuts in the fourth quarter have led to a decrease in mortgage rates, resulting in increased refinancing activities and origination volumes [4]. - A significant portion of NLY's mortgage-backed securities (MBS) holdings is expected to have experienced elevated prepayment rates, positively impacting net premium amortization and supporting growth in interest income and average asset yield [5]. Servicing Income - Slower prepayment speeds are likely to have positively affected the company's mortgage servicing rights portfolio, which is anticipated to increase servicing fees in the upcoming quarter [6]. - The Zacks Consensus Estimate for net servicing income is projected at $137.4 million, representing a year-over-year increase of 18.9% [6]. Earnings Surprise Potential - The current model indicates that an earnings beat is unlikely for NLY, as it lacks the necessary combination of a positive Earnings ESP and a Zacks Rank higher than 3 [7]. - Annaly currently holds a Zacks Rank of 3, indicating a hold position [9].

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for profitable short-term investing, highlighting the need for sound fundamentals and positive earnings revisions to maintain momentum. Group 1: Trend Analysis - The trend in short-term investing is crucial, and confirming its sustainability is essential for profitability [1][2] - Stocks that show recent price strength, particularly those trading near their 52-week high, are indicative of bullish trends [3] Group 2: Company Spotlight - Betterware de Mexico SAPI de C (BWMX) - BWMX has demonstrated a solid price increase of 31.4% over the past 12 weeks, indicating strong investor interest [4] - The stock has increased by 38.5% in the last four weeks, suggesting that the upward trend is still intact [5] - BWMX is currently trading at 94% of its 52-week high-low range, indicating a potential breakout [5] Group 3: Fundamental Strength - BWMX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6] - The Zacks Rank system has shown that stocks rated 1 have generated an average annual return of +25% since 1988, indicating strong historical performance [7] - The Average Broker Recommendation for BWMX is also 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7] Group 4: Additional Opportunities - Besides BWMX, there are other stocks that meet the "Recent Price Strength" criteria, suggesting further investment opportunities [8] - The article mentions the availability of over 45 Zacks Premium Screens to help investors find winning stock picks based on their investing style [8]

Core Insights - Ameriprise Financial, Inc. (AMP) is expected to report fourth-quarter and 2025 results on January 29, with anticipated year-over-year increases in revenues and earnings [1][8] Financial Performance Expectations - The Zacks Consensus Estimate for AMP's management and financial advice fees is $2.89 billion, reflecting a 6.6% increase from the prior-year quarter [3] - The estimate for distribution fees stands at $557 million, indicating a 3.9% year-over-year growth [3] - Other revenues are expected to reach $135 million, suggesting a 6.3% increase [3] - Net investment income is projected at $841 million, which represents a 5.7% decline year-over-year [4] - Premiums, policy, and contract charges are estimated at $412 million, indicating an 8.7% rise [4] - Total assets under management (AUM) and assets under administration (AUA) are expected to be $1.63 trillion, reflecting a 7.1% increase from the previous year [4][8] Cost Management and Earnings Outlook - While cost management initiatives have controlled general and administrative expenses, overall costs are expected to be elevated due to technology upgrades and hiring [5] - The consensus estimate for quarterly earnings is $10.29 per share, indicating a 9.9% increase from the prior-year quarter [7][8] - The full-year earnings estimate is $38.72, suggesting a 12.7% rise from the previous year [7] Revenue Projections - The total quarterly sales estimate is $4.71 billion, which indicates a 5.5% year-over-year increase [9] - The sales estimate for 2025 is projected at $18.06 billion, reflecting a 5.7% increase from the previous year [9] Earnings Surprise History - Ameriprise has a strong earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the last four quarters, with an average beat of 3.4% [2] - The company has a positive Earnings ESP of +1.87% and a Zacks Rank of 3 (Hold), indicating a high likelihood of beating the consensus estimate this time [6]

Core Viewpoint - Tesla is set to report its Q4 2025 earnings on January 28, with expectations of growth in its Energy Generation and Storage business despite a decline in vehicle deliveries [2]. Group 1: Tesla's Performance - Tesla's Q3 production totaled 447,450 units, a 5% year-over-year decline, while Q4 deliveries reached a record 497,099 cars, up 7.4% from the previous year [3]. - Total automotive revenues for Tesla were $21.2 billion, reflecting a 6% year-over-year increase, surpassing estimates of $18.86 billion [4]. - Energy Generation and Storage revenues were $3.4 billion in Q3 2025, a 44% increase year-over-year, exceeding estimates of $2.9 billion [5]. Group 2: Energy Generation and Storage Business - The Energy Generation and Storage segment is experiencing robust growth, driven by strong demand for products like Megapack and Powerwall [6]. - In Q4, Tesla deployed 14.2 GWh of energy storage products, setting a new record, with expected revenues of $3.4 billion, indicating an 11% year-over-year increase [7]. - The segment boasts a gross margin estimate of 31.1%, an improvement of 5.9 percentage points from the previous year, highlighting its profitability [8]. Group 3: Earnings Projections - The Zacks Consensus Estimate for Tesla's upcoming quarter is $25.11 billion in sales and earnings of 44 cents per share, with a slight decrease in the earnings estimate over the past month [9]. - Tesla's current Earnings ESP is +3.15%, but the model does not predict a definitive earnings beat due to a lack of favorable conditions [10]. Group 4: Competitor Insights - Cummins Inc. is expected to report Q4 results on February 5, with an Earnings ESP of +4.82% and a Zacks Rank of 3 [11]. - BorgWarner is scheduled to report on February 11, with an Earnings ESP of +4.47% and a Zacks Rank of 3 [12]. - Rivian Automotive, set to report on February 12, has an Earnings ESP of +12.02% and a Zacks Rank of 3 [13].

Company Performance - Medpace's stock closed at $588.05, down 3.01%, underperforming the S&P 500's gain of 0.03% on the same day [1] - Over the past month, Medpace's stock has increased by 6.02%, outperforming the Medical sector's slight loss of 0.01% and the S&P 500's gain of 0.6% [1] Upcoming Earnings - Medpace is set to release its earnings report on February 9, 2026, with an expected EPS of $4.18, reflecting a 13.9% increase year-over-year [2] - Revenue is anticipated to reach $681.17 million, indicating a 26.94% rise compared to the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, representing increases of 17.18% and no change, respectively, from the previous year [3] - Recent revisions to analyst forecasts for Medpace are crucial as they reflect short-term business trends and can indicate analysts' positive outlook on the company's health and profitability [3] Valuation Metrics - Medpace currently has a Forward P/E ratio of 36.47, which is significantly higher than the industry average Forward P/E of 16.37 [5] - The company has a PEG ratio of 2.04, compared to the industry average PEG ratio of 1.92 [6] Industry Ranking - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 188, placing it in the bottom 24% of over 250 industries [6] - The Zacks Industry Rank evaluates the performance of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Company Performance - Pacific Biosciences of California (PACB) closed at $2.58, reflecting a decrease of -3.37% from the previous day's closing price, underperforming the S&P 500's daily gain of 0.03% [1] - Over the past month, PACB shares have increased by 42.02%, outperforming the Medical sector's slight loss of -0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts anticipate that Pacific Biosciences will report earnings of -$0.19 per share, indicating a year-over-year growth of 5% [2] - For the entire fiscal year, the Zacks Consensus Estimates project earnings of -$1.89 per share and revenue of $0 million, representing changes of -127.71% and 0% from the prior year, respectively [2] Analyst Estimates - Recent changes to analyst estimates for Pacific Biosciences reflect shifting short-term business dynamics, with positive revisions indicating optimism about the business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides an actionable rating system for investors [4] Zacks Rank and Industry Performance - The Zacks Rank system ranges from 1 (Strong Buy) to 5 (Strong Sell), with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Pacific Biosciences currently holds a Zacks Rank of 3 (Hold), with the consensus EPS projection remaining stagnant over the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 92, placing it in the top 38% of all industries [6]

Company Performance - Trip.com (TCOM) stock increased by 1.26% to $62.88, outperforming the S&P 500's daily gain of 0.03% [1] - Over the last month, TCOM shares decreased by 14.04%, while the Consumer Discretionary sector lost 3.17% and the S&P 500 gained 0.6% [1] Upcoming Financial Results - The upcoming EPS for Trip.com is projected at $0.72, indicating a 20.00% increase compared to the same quarter of the previous year [2] - Revenue is estimated to be $2.1 billion, reflecting a 20.05% increase compared to the same quarter of the previous year [2] Annual Forecast - Zacks Consensus Estimates forecast earnings of $6.38 per share and revenue of $8.71 billion for the year, showing changes of +77.72% and 0%, respectively, compared to the previous year [3] - Recent analyst estimate revisions indicate optimism regarding Trip.com's business and profitability [3] Analyst Ratings - The Zacks Rank system rates Trip.com as 1 (Strong Buy), with a historical average annual return of +25% for stocks rated 1 since 1988 [5] - The Zacks Consensus EPS estimate has remained stagnant over the past month [5] Valuation Metrics - Trip.com has a Forward P/E ratio of 14.64, which is lower than its industry's Forward P/E of 17.9, indicating a valuation discount [6] - The company holds a PEG ratio of 1.84, compared to the Leisure and Recreation Services industry's average PEG ratio of 1.47 [6] Industry Context - The Leisure and Recreation Services industry, part of the Consumer Discretionary sector, has a Zacks Industry Rank of 181, placing it in the bottom 27% of over 250 industries [7] - Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]